Allegra Articles
Preliminary US court injunction against Dr Reddy’s generic Allegra sees Indian firm’s shares drop
15 June 2010
Teva returns to profit, as 4th quarter 2009 sales leap 33%
16 February 2010
Sanofi-Aventis to buy consumer health firm Chattem for $1.9 billion, aiming for bigger role in OTC
22 December 2009
Record sales for Sanofi Japan, says president
14 April 2009
Stock Commentary - New York week to May 26, 2008
2 June 2008
Sanofi-Aventis
5 May 2008
Rx-to-OTC switching making comeback
21 April 2008
Sciele and Sanofi extend Allergra accord
10 March 2008
Generics, including Plavix, and govt cost-cutting hit Sanofi-Aventis' 3rd-qtr results
6 November 2006
Sanofi-Aventis sales slow on competition
6 February 2006
Stock Commentary - Europe - week to Jan 30
6 February 2006
Stock Commentary - New York week toSept 12
19 September 2005
Stock Commentary - Europe - week to Sept 12
19 September 2005
Prasco in deal for generic Allegra
19 September 2005
Sanofi-Aventis gets competition from Teva and Barr Allegra generics deal
12 September 2005
Barr gets final US appro for generic Allegra
5 September 2005
Sanofi-Aventis' Allegra-D available in USA
8 August 2005
Strong 2nd qtr for Sanofi-Aventis
25 July 2005
Japan stock market week to May 9
16 May 2005
Barr eligible for exclusivity on generic Allegra-D
18 April 2005
Update on Barr/Aventis Allegra patent dispute
11 April 2005
IMPAX intervenes in Barr litigation
7 March 2005
Barr sues FDA over generic Allegra
14 February 2005
Sanofi-Aventis 2004 sales rise 10%
31 January 2005
US uninsured "pay 78% more than best Rx prices"
1 November 2004
Sanofi-Aventis' 3rd-qtr sales rise 10.7%
1 November 2004
Butterbur no benefit for hay fever sufferers
6 September 2004
Aventis posts flat 2nd-qtr 2004 earnings
2 August 2004
FDA set to speed US Rx-OTC switches?
12 July 2004
Stock Commentary - Europe
12 July 2004
Stock Commentary - New York
12 July 2004
Barr and Pfizer win patent litigations
12 July 2004
Aventis' sales grow 7.1% but Allegra falls
3 May 2004
Aventis files new Allegra patent infringement suits
15 March 2004
Aventis rejects Sanofi-Synthelabo's $60 billion hostile bid
2 February 2004
Options for a P&G/Aventis link-up reviewed by broker Natexis
26 January 2004
Aventis sells pharma plant to Famar
19 January 2004
Aventis submits NDA for once-daily Alegra
5 January 2004
Aventis/Sanofi-Synthelabo merger rumors resurface
15 December 2003
Aventis disposes of Behring unit with $925M sale to Australia's CSL
15 December 2003
Stock Commentary - Europe
11 August 2003
Aventis on target as performance picks up
4 August 2003
US FDA "has authority for Rx-OTC switches"
5 May 2003
$1.1 bill buyback at Aventis as profits fall
5 May 2003
California directs HMOs over switched drugs
7 April 2003
Dr Reddy's Allegra clone
31 March 2003
Sepracor improves position in 2002
10 February 2003
Aventis blockbusters driving growth
6 May 2002
Allegra approved for new treatment
29 April 2002
Unnamed Aventis product terminated
25 March 2002
New use for Allegra?
11 March 2002
US HHS Sec backs "some" OTC switches
18 February 2002
FDA to review IMPAX ANDA for Allegra-D generic
18 February 2002
Barr and Aventis file suit over Allegra-D patents
4 February 2002
US Rx "pull-through" programs viewed
4 December 2001
Aventis growth driven by strong US pharmaceutical sales
6 November 2001
Aventis still confident about hitting 35% earnings rise for 2001
27 September 2001
Stock Commentary - Europe
12 July 2001
US FDA discusses third-party OTC switch call
25 June 2001
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
